View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 16, 2021

Memic agrees to merge with MedTech Acquisition

The combined firm will operate as Memic on concluding the deal, with an expected pro-forma equity value of more than $1bn.

Israel-based medical device company Memic Innovative Surgery has signed a definitive business combination agreement with special purpose acquisition company MedTech Acquisition.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

Founded in 2013, Memic focuses on developing surgical robotic technology.

The company’s Hominis platform is the first US Food and Drug Administration (FDA) cleared surgical robot to feature miniature humanoid-shaped arms, with shoulder, elbow and wrist joints.

On closing the deal, the combined entity is estimated to have a pro-forma equity value of more than $1bn, assuming there are no redemptions by MedTech’s public stakeholders.

Memic’s current stakeholders will place all their equity in the merged company.

Memic CEO Dvir Cohen said: “Our partnership with the MedTech team, which provides decades of collective experience in surgical robotics, is an important step in bringing our advanced technology to medical facilities and patients across the United States and the world.

“We look forward to entering the public markets and working together with MedTech in the next phase of our company’s journey.”

The combined entity will operate as Memic on concluding the transaction. MedTech independent director and current board chairman Maurice Ferré will serve as executive chairman of the merged business.

MedTech Acquisition CEO Chris Dewey said: “Following a comprehensive review of investment opportunities, we were impressed with the highly accomplished management team at Memic and its disruptive, minimally invasive, cost-effective Hominis system, which positions [Memic] well for substantial growth and profitability.

“We believe that Memic’s innovative technology, coupled with our team’s expertise in successfully commercialising medical device companies, has the potential to create significant value for stockholders in the years ahead.”

Both companies’ Boards of Directors have approved the merger.

The deal is expected to close in the fourth quarter of this year subject to approval from both companies’ stockholders and other customary conditions.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network